Modality
Gene Therapy
MOA
PI3Ki
Target
SGLT2
Pathway
Notch
LGS
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
Dec 2021
→ Oct 2030
Phase 1Current
NCT06882797
288 pts·LGS
2022-11→2025-05·Terminated
NCT08740177
2,196 pts·LGS
2021-12→2030-10·Recruiting
2,484 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-1411mo agoPh2 Data· LGS
2030-10-014.5y awayPh2 Data· LGS
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Recruit…
P1/2
Termina…
Catalysts
Ph2 Data
2025-05-14 · 11mo ago
LGS
Ph2 Data
2030-10-01 · 4.5y away
LGS
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06882797 | Phase 1/2 | LGS | Terminated | 288 | SeizFreq |
| NCT08740177 | Phase 1/2 | LGS | Recruiting | 2196 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 |